InSite Vision Announces Positive Phase 3 Results for BromSite

BromSite (ISV-303; InSite Vision Inc.) achieved statistically significant superiority compared with DuraSite (InSite Vision Inc.) alone in alleviating ocular pain and inflammation after cataract surgery in a phase 3 clinical trial, according to a company news release. BromSite combines a low dose (0.075%) of the nonste...

Full Story →